| Issuer | % of Class | Filed |
|---|---|---|
|
Stoke Therapeutics Inc
13G/A
Amendment 2
STOK · 86150R107
|
0% |
11/14/2025
Event 9/30/2025
|
|
UroGen Pharma Ltd.
13G/A
Amendment 2
URGN · M96088105
|
0% |
11/14/2025
Event 9/30/2025
|
|
Stoke Therapeutics Inc
13G/A
Amendment 1
STOK · 86150R107
|
5.8% |
7/29/2025
Event 6/30/2025
|
|
UroGen Pharma Ltd.
13G/A
Amendment 1
URGN · M96088105
|
6.9% |
7/29/2025
Event 6/30/2025
|
|
UroGen Pharma Ltd.
13G
URGN · M96088105
|
5.8% |
6/13/2025
Event 6/9/2025
|
|
Breeze Holdings Acquisition Corp
13G/A
Amendment 1
BRZH · 106762107
|
0% |
5/12/2025
Event 3/31/2025
|
|
Exagen Inc.
13G/A
Amendment 1
XGN · 30068X103
|
5.0%
Checked 5% or less
|
5/12/2025
Event 3/31/2025
|
|
Tarsus Pharmaceuticals Inc.
13G/A
Amendment 2
TARS · 87650L103
|
4.9% |
2/13/2025
Event 12/31/2024
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.